Surmasis Reprimanded for Lab Records, Equipment Inspections

Drug GMP Report
A A
The FDA hit Surmasis Pharmaceutical of Des Moines, Iowa with a Form 483 after a February inspection revealed problems with laboratory records, computer systems and equipment inspections.

To View This Article:

Login

Subscribe To Drug GMP Report